

No.	商品名・サービス名	論文名
1	スパイラルアレイ	Spiral array: a new high-throughput technology covers tissue heterogeneity. Junya Fukuoka et.al. Arch Pathol Lab Med 2012 Nov;136(11):1377-84. DOI: 10.5858/arpa.2011-0393-OA
2	スパイラルアレイ	Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research Akira Komiya et.al. Int J Oncol. 2014, 44 (1): 195-202. DOI:10.3892/ijo.2013.2173
3	スパイラルアレイ	Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered Kazuhiro Tabata et.al. BMC Clin Pathol. 2014;14: 23. DOI: 10.1186/1472-6890-14-23
4	スパイラルアレイ	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. Sayuri Nakamura et.al. PLoS One. 2017 Oct 19;12(10) DOI:10.1371/journal.pone.0186192
5	スパイラルアレイ	High Expression Level of Serpin Peptidase InhibitorClade E Member 2 is Associated with PoorPrognosis in Lung Adenocarcinoma. Ryota Dokuni et.al. DOI: 10.21203/rs.3.rs-51737/v1
6	スパイラルアレイ	Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma. Nanako Miwa et.al. Onco Targets Ther. 2020 Sep 10;13:9005-9013 DOI:10.2147/OTT.S265539
7	TMA	Discovery of Colorectal Cancer Biomarker Candidates by Membrane Proteomic Analysis and Subsequent Verification using Selected Reaction Monitoring (SRM) and Tissue Microarray (TMA) Analysis. Hideaki Kume et.al. Molecular & Cellular Proteomics, 2014, 13 (6) 1471-1484] DOI:10.1074/mcp.M113.037093
8	TMA	The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action. Yukiko Matsumura et.al. Mol Pain 2014 Sep 21;10:61. DOI:10.1186/1744-8069-10-61
9	TMA	SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. Kazutoshi Komiya e.al. Onco Targets Ther.2016 Oct 27;9:6663-6668. DOI: 10.2147/OTT.S114492
10	TMA	REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Yusuke Sato et.al. Ann Surg Oncol.2013 Sep;20(9):3044-51. DOI: 10.1245/s10434-013-2983-9
11	TMA	CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma. Yusuke Sato et.al. Ann Surg Oncol. 2016 Mar;23(3):936-42. DOI: 10.1245/s10434-015-4909-1

12	TMA	<p>PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. Akiyuki Wakita et. al. Anticancer Res. 2017 Mar;37(3):1433-1441.</p> <p>DOI:10.21873/anticancerres.11467</p>
13	TMA	<p>Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma. Yuta Kawakita et. al. Surg Today.2017 Nov;47 (11) :1312-1320</p> <p>DOI: 10.1007/s00595-017-1514-x</p>
14	TMA	<p>TLR3 expression status predicts prognosis in patients with advanced thoracic esophageal squamous cell carcinoma after esophagectomy. Yusuke Sato et.al. Am J Surg. 2018 Aug;216(2):319-325.</p> <p>DOI: 10.1016/j.amisurg.2018.01.038</p>
15	TMA	<p>Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. Aung Kyi Thar Min et. al. Cancer Med. 2018 Jul;7(7):3321-3330.</p> <p>DOI:10.1002/cam4.1564</p>
16	TMA	<p>Expression, Function, and Prognostic Value of MAGE-D4 Protein in Esophageal Squamous Cell Carcinoma. Yasuo Ono et.al. Anticancer Res. 2019 Nov; 39 (11): 6015-6023</p> <p>DOI:10.21873/anticancerres.13807</p>
17	TMA	<p>High TLR4 expression predicts a poor prognosis after esophagectomy for advanced thoracic esophageal squamous cell carcinoma. Yusuke Sato et.al. Esophagus. 2020 Oct;17(4):408-416.</p> <p>DOI: 10.1007/s10388-020-00732-x</p>
18	TMA	<p>Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma. Hayato Baba et.al. Ann Surg Oncol. 2020 Sep;27(9):3247-3256.</p> <p>DOI: 10.1245/s10434-020-08431-8</p>
19	TMA	<p>Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. Sei Ueda et. al. Cancer Genomics Proteomics. 2020 Jul-Aug;17(4):391-400.</p> <p>DOI: 10.21873/cgp.20198</p>
20	TMA	<p>m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Yushi Nagaki et al. Genes Cells. 2020 Aug;25(8):547-561.</p> <p>DOI:10.1111/gtc.12792</p>
21	TMA	<p>IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma. Akiyuki Wakita et. al. J Surg Res. 2021 Mar;259:137-144.</p> <p>DOI: 10.1016/j.jss.2020.10.024</p>
22	TMA	<p>High TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma. Yusuke Sato et.al. Curr Oncol. 2023 May 4;30(5):4724-4735.</p> <p>DOI:10.3390/curroncol30050356</p>

23	カクテル抗体	Difference of Morphology and Immunophenotype between Central and Peripheral Squamous Cell Carcinomas of the Lung. Tomayoshi Hayashi et.al. Biomed Res Int. 2013;2013:157838. DOI: 10.1155/2013/157838
24	カクテル抗体	How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations? Akito Hata et.al. J Thorac Oncol. 2013 Jan;8(1):89-95. DOI: 10.1097/JTO.0b013e31827690b5
25	カクテル抗体	A case of napsin A-positive metastatic lung cancer originating from the colon. Tomokazu Ito et.al. Surg Case Rep. 2017 Nov 9;3(1):114. DOI: 10.1186/s40792-017-0389-9
26	バイオバンク	Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Junya Fujimoto et.al. Int J Cancer. 2017 Oct 15;141(8):1589-1599 DOI:10.1002/ijc.30851
27	バイオバンク	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Xin Hu et.al Nat Commun. 2019 Jul 5;10(1):2978 DOI:10.1038/s41467-019-10877-8
28	デジタル病理学	A narrative review of digital pathology and artificial intelligence: focusing on lung cancer. Taro Sakamoto et.al. Transl Lung Cancer Res2020 DOI:10.21037/tlcr-20-591
29	Tissue Protector	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group Lung Cancer. 2012 Apr;76(1):1-18. Erik Thunnissen et.al DOI:10.1016/j.lungcan.2011.10.017
30	Tissue Protector	Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma JOURNAL OF GYNECOLOGIC ONCOLOGY.2022 Sep;33 (5) :e67. Tamaki Tanaka et.al DOI:10.3802/jgo.2022.33.e67

※リンクを張ることが可能なものには、DOIにリンクを張っております。